Partner in relationship

BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody

4 weeks ago talkbio0Tagged 30%, BioAtla, CAB, Partner in relationship, Staff

Staff, Partner in relationship, CAB, BioAtla, 30%

Sofinnova Partners Launches Three New Biotechs with €165M Acceleration Fund

1 month ago talkbio0Tagged Acceleration, BioClec, Funds, Partner in relationship, pharmaceutical backing, Sofinnova, venture

Sofinnova Partners, biotech acceleration fund, BioClec, Forth Therapeutics, Signadori Bio, venture capital, pharmaceutical backing

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

3 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners

Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment

4 months ago talkbio0Tagged Arch of foot, Denali, F-Prime Capital, Mubadala, Neurological diseases, Partner in relationship, small molecule therapies, Tenvie, venture

Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital

Walgreens Boots Alliance in Negotiations for Potential Sale to Private Equity Firm Sycamore Partners

4 months ago talkbio0Tagged Boots Alliance, Health care facility, Industry, Partner in relationship, Platanus occidentalis whole extract, private equity sale, Walgreens

Walgreens Boots Alliance, Sycamore Partners, private equity sale, retail industry, healthcare retail

Evotec Shares Soar as Private Equity Firm Triton Considers Takeover Bid

5 months ago talkbio0Tagged Drug Development, Evotec, Partner in relationship, Private Equity, Triton - satellite of Neptune, Twice a day

Evotec, Triton Partners, takeover bid, private equity, drug development, pharmaceuticals

Sanofi Receives Bids from Private Equity Firms for $16B+ Consumer Health Business

7 months ago talkbio0Tagged Bloomberg, Clayton, Consumer, health business, Partner in relationship, Plasminogen Inactivators, private equity firms, sanofi

Sanofi, private equity firms, consumer health business, PAI Partners, Clayton, Dubilier & Rice, Bloomberg

UCB’s Strategic Shift: Bristol Myers ADC Partner’s CEO Takes the Helm

12 months ago talkbio0Tagged Administration occupational activities, CEO, Changing, Drug Industry, Myers, Partner in relationship, strategic shift, therapeutic autologous dendritic cells, UCB

UCB, management changes, CEO, Bristol Myers, ADC partner, strategic shift, pharmaceutical industry.

Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal

12 months ago talkbio0Tagged Biopharma, CAR-T, Cellares, diversification, Generalized, Manufacture, Myers, Partner in relationship

Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal

Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO

1 year ago talkbio0Tagged Arch of foot, Backed, Bayer, bleomycin/dacarbazine/lomustine/vincristine, Boundless, Checkpoint Kinase 1 Inhibitors, extrachromosomal DNA, IPO, Nasdaq Listing, Oncology Startup, Partner in relationship, Phase 1 Trials, Preliminary, Public Offering, Second Half of 2024, small molecule drugs, symbol

Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024